Damon Runyon Researchers

Meet Our Scientists
Jonathan E. Shoag, MD

Prostate cancer is the second leading cause of cancer death in men in the United States. Remarkably, work over the past decade has demonstrated that even the worst prostate cancers are dependent on the same signaling pathways that govern normal prostate behavior. Dr. Shoag’s objective is to identify drugs that have activity against the normal prostate and can be used to understand and treat prostate cancer. Dr. Shoag will apply novel statistical and machine learning approaches on large scale clinical data to discover new therapies and pathways important in prostate cancer. He will then test these therapies in genetically engineered and patient-derived prostate cancer models. Identifying active drugs against prostate cancer that are already FDA-approved or have been previously studied in clinical trials for other cancers can aid in understanding prostate cancer biology and can rapidly benefit patients with advanced disease.

Project title: "Harnessing clinical data to identify new prostate cancer therapeutics"
Institution: University Hospitals Cleveland Medical Center
Award Program: Physician-Scientist
Sponsor(s) / Mentor(s): Christopher E. Barbieri, MD, PhD
Cancer Type: Prostate
Research Area: Drug Discovery